Exome Asset Management’s AstraZeneca AZN Stock Holding History

Exome Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,181	Closed	-$3.93M	–	75
2025 Q2	$3.93M	Buy	+14,181	New	+$1.99M	2.92%	7

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Exome Asset Management's AZN Position: Q2 2026 in Review

Exome Asset Management opened a new position in AstraZeneca (AZN) in Q2 2026: 12,045 shares worth $2.25M. The stake represents 1.39% of the portfolio and ranks #27 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in AZN as recently as Q4 2025.

Exome Asset Management first reported a position in AZN in Q1 2025 and has held it in 4 quarters since. The position peaked at $5.26M in Q4 2025. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Exome Asset Management held 12,045 shares of AstraZeneca worth $2.25M as of Q2 2026.
AstraZeneca was a new Exome Asset Management position in Q2 2026.
AstraZeneca made up 1.39% of Exome Asset Management's portfolio in Q2 2026, its #27 holding.
Exome Asset Management first reported a position in AstraZeneca in Q1 2025 and has held it in 4 quarters since.
Exome Asset Management's AstraZeneca position peaked at $5.26M in Q4 2025.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.